腹膜透析低钾血症患者补钾疗效:一项随机对照试验
这项多中心、开放标签、前瞻性随机对照试验纳入167例腹膜透析低钾血症患者,比较方案化口服氯化钾补钾(维持血钾4-5 mEq/L)与常规补钾(血钾<3.5 mEq/L时补充)对腹膜炎的影响。方案化组首次腹膜炎发生时间显著延长,腹膜炎风险显著降低(HR 0.47),次要结局无显著差异。
要点
- 方案化补钾维持血钾4-5 mEq/L可延长首次腹膜炎时间并降低腹膜炎风险。
- 方案化组血钾升高至4.36±0.70 mEq/L,常规组为3.57±0.65 mEq/L。
- 方案化组3例(4%)出现无症状高钾血症(>6 mEq/L)且无特征性心电图改变。
核心结论
- 与血钾低于3.5 mEq/L时反应性补钾相比,方案化口服补钾维持血钾4-5 mEq/L可能降低腹膜透析低钾血症患者的腹膜炎风险。
研究设计与样本
- 多中心、开放标签、前瞻性随机对照试验,纳入167例成人腹膜透析低钾血症患者,来自6个腹膜透析中心,85例分配至方案化治疗组,82例分配至常规治疗组。
- 随机化按中心和残余尿量(≤100或>100 mL/day)分层,干预52周,采用意向性治疗分析和Cox比例风险回归比较。
主要发现
- 方案化组血钾升高至4.36±0.70 mEq/L,常规组为3.57±0.65 mEq/L,平均差异0.66(95% CI,0.53-0.79)mEq/L,P < 0.001。
- 方案化组首次腹膜炎中位时间显著长于常规组(223 [IQR,147-247] vs 133 [IQR,41-197]天,P = 0.03)。
- 与常规治疗相比,方案化组腹膜炎风险显著降低(HR,0.47 [95% CI,0.24-0.93]),次要结局均无显著差异。
- 方案化组3例(4%)出现无症状高钾血症(>6 mEq/L)且无特征性心电图改变。
关键数值与推荐
- 低钾血症定义为过去6个月内至少3次血钾值或平均血钾值<3.5 mEq/L。
- 方案化补钾为可滴定剂量口服氯化钾,维持血清钾4-5 mEq/L;常规补钾为血清钾<3.5 mEq/L时反应性补充。
临床怎么用
- 作者认为,对于腹膜透析低钾血症患者,方案化口服补钾维持血钾4-5 mEq/L可能降低腹膜炎风险。
局限性
- 非双盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Hypokalemia is a common electrolyte abnormality in patients on peritoneal dialysis (PD) and has been associated with increased risks of peritonitis and death. Whether correction of hypokalemia improves these outcomes is unknown. STUDY DESIGN: Multicenter, open-label, prospective, randomized controlled trial. SETTING & PARTICIPANTS: Adult (aged ≥18 years) PD patients with hypokalemia (defined as at least 3 values or an average value <3.5 mEq/L in the past 6 months). Randomization was stratified according to center and residual urine output (≤100 or >100 mL/day). INTERVENTIONS: Random assignment to either protocol-based potassium supplementation (titratable dose of oral potassium chloride to maintain serum potassium of 4-5 mEq/L) or conventional potassium supplementation (reactive supplementation when serum potassium is <3.5 mEq/L) over 52 weeks. Treatment groups were compared using intention-to-treat analyses implemented using Cox proportional hazards regression. OUTCOME: The primary outcome was time from randomization to first peritonitis episode (any organism). Secondary outcomes were all-cause mortality, cardiovascular mortality, hospitalization, and conversion to hemodialysis. RESULTS: A total of 167 patients with time-averaged serum potassium concentrations of 3.33 ± 0.28 mEq/L were enrolled from 6 PD centers: 85 were assigned to receive protocol-based treatment, and 82 were assigned to conventional treatment. The median follow-up time was 401 (IQR, 315-417) days. During the study period, serum potassium levels in the protocol-based treatment group increased to 4.36 ± 0.70 mEq/L compared with 3.57 ± 0.65 mEq/L in the group treated conventionally (mean difference, 0.66 [95% CI, 0.53-0.79] mEq/L; P < 0.001). The median time to first peritonitis episode was significantly longer in the protocol-based group (223 [IQR, 147-247] vs 133 [IQR, 41-197] days, P = 0.03). Compared with conventional treatment, the protocol-based group had a significantly lower hazard of peritonitis (HR, 0.47 [95% CI, 0.24-0.93]) but did not differ significantly with respect to any of the secondary outcomes. Asymptomatic hyperkalemia (>6 mEq/L) without characteristic electrocardiographic changes occurred in 3 patients (4%) in the protocol-based treatment group. LIMITATIONS: Not double-masked. CONCLUSIONS: Compared with reactive potassium supplementation when the serum potassium level falls below 3.5 mEq/L, protocol-based oral potassium treatment to maintain a serum potassium concentration in the range of 4-5 mEq/L may reduce the risk of peritonitis in patients receiving PD who have hypokalemia. TRIAL REGISTRATION: Registered at the Thai Clinical Trials Registry with study number TCTR20190725004.
引用
- Pichitporn W, Kanjanabuch T, Phannajit J, et al. Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. Am J Kidney Dis. 2022. PMID: 35597332. doi:10.1053/j.ajkd.2022.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。